Madrigal Pharmaceuticals (MDGL) Expected to Announce Earnings on Tuesday

Key Points

• Madrigal Pharmaceuticals is expected to report Q3 2026 results before the market opens on November 3. Analysts forecast a loss of $0.86 per share and revenue of approximately $404.2 million.
• The company’s latest quarter exceeded expectations, with revenue rising 71.2% year over year to $364.3 million and EPS of ($1.99), better than the consensus estimate of ($2.68).
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $699.20, although insiders sold shares primarily to cover tax obligations under pre-arranged trading plans.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) is expected to be announcing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Madrigal Pharmaceuticals to post earnings of ($0.8629) per share and revenue of $404.17 million for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.99) EPS for the quarter, topping the consensus estimate of ($2.68) by $0.69. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 56.65%. The company had revenue of $364.25 million during the quarter, compared to the consensus estimate of $352.13 million. During the same period last year, the firm earned ($1.90) EPS. Madrigal Pharmaceuticals's revenue for the quarter was up 71.2% on a year-over-year basis. On average, analysts expect Madrigal Pharmaceuticals to post ($7.03) EPS for the current fiscal year and $5.30 EPS for the next fiscal year.

Madrigal Pharmaceuticals Stock Up 0.8%

Madrigal Pharmaceuticals stock opened at $437.74 on Tuesday. The firm has a 50 day simple moving average of $506.16 and a 200 day simple moving average of $501.82. The company has a current ratio of 3.20, a quick ratio of 2.94 and a debt-to-equity ratio of 0.65. Madrigal Pharmaceuticals has a 1-year low of $393.61 and a 1-year high of $615.00. The firm has a market capitalization of $10.11 billion, a price-to-earnings ratio of -33.96 and a beta of -1.04.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Citigroup started coverage on Madrigal Pharmaceuticals in a research report on Wednesday, September 23rd. They set a "buy" rating and a $725.00 target price on the stock. The Goldman Sachs Group initiated coverage on Madrigal Pharmaceuticals in a research report on Thursday, September 24th. They issued a "buy" rating and a $704.00 price target for the company. Wells Fargo & Company began coverage on Madrigal Pharmaceuticals in a research note on Monday, July 27th. They set an "overweight" rating and a $685.00 price objective on the stock. Wolfe Research raised Madrigal Pharmaceuticals from a "peer perform" rating to an "outperform" rating and set a $605.00 price objective on the stock in a report on Tuesday, August 4th. Finally, HC Wainwright restated a "buy" rating on shares of Madrigal Pharmaceuticals in a research note on Friday, July 31st. Fifteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Madrigal Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $699.20.

Insider Transactions at Madrigal Pharmaceuticals

In related news, CEO William Sibold sold 5,221 shares of the firm's stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $542.39, for a total value of $2,831,818.19. Following the sale, the chief executive officer directly owned 197,746 shares of the company's stock, valued at $107,255,452.94. This trade represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Shannon T. Kelley sold 664 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $514.97, for a total transaction of $341,940.08. Following the completion of the sale, the general counsel directly owned 11,474 shares in the company, valued at $5,908,765.78. This represents a 5.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 12,247 shares of company stock valued at $6,581,182. Corporate insiders own 17.60% of the company's stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal's lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.